The University of Warwick Library - WebBridge

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Earl, Helena M..  The Lancet.  v. 393. no. 10191.   2019-06-06. p. 2599 - 2612... issn: 0140-6736 .   

Online access not found

Sorry - based on the information provided, WebBridge cannot offer appropriate links.